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The concept of multitest screening for hemato-
logical disorders is not necessarily a new one. Imple-
mentation of such ideas has recently become possible, 
for the automated electronic instruments perform-
ing sequential multiple analyses within very short 
periods of time are a very significant advancement 
in the technology of the hematology laboratory. It 
must be emphasized, however, that the value of such 
instrumentation lies not only in the rapidity, but also 
in the accuracy and precision as well as the number 
and nature of the tests performed. While the data on 
samples have been reported on individual patients 
three and a half years in our hematology laboratory, 
it is only within the past few months that examples 
of its utilization for screening studies have begun to 
appear in the literature (1, 3, 5) . 
Several automated instruments are available 
that perform the routine counting and sizing of cells 
in the blood. The Coulter model "S" is the one most 
widely used ( 2) . This is the instrument we use and 
it is the one used in the studies to be cited here. It 
is an instrument that reports on seven parameters, 
measuring the WBC, RBC, and mean corpuscular 
volume (MCV), and utilizing the latter two com-
puting the hematocrit and then the mean corpuscular 
hemoglobin (MCH) and mean corpuscular hemo-
globin concentration (MCHC). The time required 
from the time of sample aspiration until the results 
of the seven determinations are printed is 40 seconds. 
I must emphasize that not only speed is achieved, 
but precision and accuracy are far greater than many 
previously used methods. Indeed, variation on repli-
cate samples is less than 1 % and accuracy appears 
to be of the same order. 
Considering the availability of such accurate 
data and the comparative ease with which they may 
be obtained, it can be seen that these instruments 
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can be valuable tools in screening for hematological 
abnormalities. Indeed here at the Medical College 
of Virginia, two interdepartmental cooperative 
studies have been conducted within the past year. 
One of these was presented in abstract form at the 
December 1972 meeting of the American Society 
of Hematology, and has recently been submitted for 
definitive publication (5). The work in large part 
was the project of Mr. Alvin Schmaier, currently a 
third-year medical student, with assistance from Drs. 
Maurer, Johnston and Scott. The other study has 
been conducted as part of a larger study in approxi-
mately 530 Black children in the Head Start Pro-
gram. These studies exemplify particularly well the 
principle of multitest screening in hematology, and 
it is to these and to a comparison of these with 
previous studies (1, 3) that I wish to address my-
self. 
I will not detail the technical operation of the 
model "S" but note here that we have had the in-
strument in operation for more than three and a half 
years. This has given us extensive experience in all 
of the positive as well as the negative qualities of 
the instrument. Because some of the parameters are 
computed, our initial efforts were to compare these 
with other methods then in operation and standardize 
the data. This was accomplished by comparative data 
obtained on 1,500 samples of EDTA anticoagulated 
blood. No significant difference was found in the 
hemoglobin determination, but the linearity was bet-
ter in the model "S" determinations than with flow-
through determinations giving greater accuracy to 
the former, particularly in the high > 16 gm and 
low < 7 gm ranges. For reasons which have never 
been satisfactorily explained either by us or by the 
manufacturer, the WBCs average approximately 
8 % lower by the model "S" than when determined 
by our alternative or electronic back-up. This dis-
crepancy is noted also in data from other institu-
tions. The lower percentage has been consistent 
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and therefore is not a factor. Finally, the compari-
son of the spun hematocrit with the computed 
hematocrit (MCV x RBC) showed the latter to 
be, on the average, 1 % higher-a difference that 
is minimal and one that certainly can be disre-
garded. I should note here that this is somewhat 
different from the study of England and Fraser 
( 1) who set the electronics so that the hema-
tocrit is 1.5% below the spun hematocrit. This 
quite possibly might allow for differences of our 
MCV norm 92 ± 6 (range 86-98) from theirs 
(80-90). Indeed Pearson, et al. ( 3), describe a 
range of 72-101 with a mean of 88.67 and a stan-
dard deviation of 5.3. 
At the outset then, it becomes important to note 
what the norms are for the population being studied 
and these should be norms for the institution. The 
data just given are presumed to be an adult popula-
tion; however, it is not clear from either of the pub-
lished reports cited above whether age differences 
were taken into consideration in their studies. The 
reason for concern with the age variability of the 
MCV data will become apparent since this parameter 
is one of the major criteria used to screen for the 
thalassemia syndromes. 
The other measured parameter of extreme im-
portance in the screening efforts is the RBC. We 
have come to regard this as extremely accurately 
measured by the model "S." In contrast to the 
earlier manual methods with an accuracy no greater 
than 20 % , we now feel the accuracy and repro-
ducibility of this measurement is on the order of 
1 % , or in the range of 50,000 RBC/µl. 
With these points in mind, I would like to dis-
cuss the application of multitest screening in hema-
tology and share some of the results we have ac-
cumulated in specific studies. The first such study 
undertaken here was a cooperative effort involving 
the divisions of Clinical Pathology, Pediatrics and 
Medicine. Mr. Alvin Schmaier, working as a summer 
extern in the Department of Pediatrics, was respon-
sible for the collection of samples anti collation of 
the data. This portion of my report is in large part 
his effort. It is a most commendable piece of work 
which recently has been submitted for publica-
tion ( 5). The data given here are reproduced with 
his permission. 
This study took advantage of the fact that defec-
tive alpha chain synthesis may occur in the neonate 
and result in the presence of the tetrameric hemo-
globin, hemoglobin Barts (gamma 4). This form of 
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hemoglobin rapidly disappears with onset of beta 
chain synthesis and by six months of age no longer 
can be identified. Cord blood studies have been per-
formed but these naturally are limited in scope. 
Alpha thalassemia heterozygotes have abnormal red 
cell indices, and if these could be identified early, it 
might be possible to select infants in the neonatal 
period, or certainly within the first few weeks of 
life, whose blood then could be subjected to hemo-
globin electrophoresis. 
Taking advantage of the fact that blood could 
be obtained by capillary puncture with the use of 
unopettes from Becton Dickinson especially for 
model "S" counters ( order no. 5840, Becton Dick-
inson, Rutherford, N. J.), Mr. Schmaier began col-
lecting capillary samples in triplicate from the new-
born nursery, of course after receiving parental 
consent. Table 1 shows the tabulation of the results. 
In particular, I want to call attention to the MCV 
and MCH. If one were to choose values for identi-
fication as suggested by other studies, one would 
select only those with values below 80 fl! Obviously, 
then the norm for this population group is quite dif-
ferent from adults, a fact that is well known ( 6). 
We were unaware, however, of the limits using the 
model "S" and these needed definition for the study. 
A total of 200 newborn Black infants was 
studied. Electrophoresis of the hemoglobin in these 
newborns showed 181 to be normal; that is, only 
hemoglobins A and F. Of the remainder, 13 showed 
an additional abnormal hemoglobin either S or C, 
while six showed the presence of hemoglobin Barts. 
Of the six, one also showed C and one S hemoglobin. 
As defined in Table 1, the lower limit of normal was 
97 fl. In the samples studied, nine infants had MCV 
less than 94 fl and MCH less than 29.5 fl. Since 
these figures are less than normal the data would be 
"suspect" and thus hemoglobin electrophoresis was 
performed. In the group of 200 studied, all had 
hemoglobin electrophoresis performed. Table 2 
shows the hemoglobin electrophoresis and pertinent 
model "S" data on those with abnormal MCV and 
MCH. It is to be noted that hypochromia can no 
longer be assessed by the MCHC ( 4); that is clearly 
shown in this table. The most s·triking findings are 
that of nine patients, six had hemoglobin Barts and 
thus the alpha thalassemia trait. These were clearly 
identified by the low MCV and low MCH. Two of 
the patients had a second abnormality in that Hgb C 
was identified in one and S in the other. In the total 
sample, 13 infants were identified who had either 
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TABLE 1 
RED CELL INDICES IN NORMAL BLACK FULL-TERM NEWBORN INFANTS 
Red Blood Cell Count ( X 106 / µI) 
Hemoglobin (g / dl) 
Hematocrit ( % ) 
Mean Corpuscular Volume (fl) 
Mean Corpuscular Hemoglobin (pg) 
Mean Corpuscular Hemoglobin Concentration (g/dl) 
s = Standard Deviation 
Constant k = L65 
Lower tolerance limit = mean-ks 
Sample size == 91 
Mean 
5.2 
18.0 
55.3 
106.4 
34. 5 
32.5 
Standard Deviation ks lower Tolerance Limit 
0.6 1.0 4.2 
2.0 3.3 14.7 
6.1 10.0 45.3 
5.7 9.4 97.0 
2 . 2 3.6 30.9 
1.0 1. 7 30.8 
For example, for the mean corpuscular volume of 106.4µ 3, the lower limit of normal is 97µ 3 (lower tolerance limit). 
Hgb Sor C but no Barts and an MCV and MCH 
within the normal limits. Thus in this study, all 
infants with alpha thalassemia were readily identified 
so that no "false negative" values were recorded. 
There apparently were three false positives, with 
data just below the norms set. Currently, there is no 
explanation for these. 
It can be seen then that Mr. Schmaier made 
a significant contribution in the study and that it 
is possible to screen infants using the multitest 
principle. As a matter of fact, the incidence of 
3 % hemoglobin Barts is consistent with the re-
ported incidence in American Blacks. 
Let me now turn to another study involving 
muHitest screening with the evaluation of RBC 
abnormality indices. Whereas the previous study 
was concerned with alpha thalassemia trait, this 
study was designed to study thalassemia traits per-
haps encompassing both alpha and beta thalas-
semias. Again, this was a cooperative study in-
volving the same divisions as those in the study 
just cited. 
The group screened was quite different, how-
ever. This was composed of 540 Black children 
most of whom were enrolled in the Head Start 
Program in Richmond. Our study was only part 
TABLE 2 
HEMATOLOGIC FINDINGS IN NINE INFANTS WITH MEAN CORPUSCULAR VOLUMES < 94 FL 
AND MEAN CORPUSCULAR HEMOGLOBINS <29.5 PG 
Infant Hgb Pattern MCV (fl) MCH (pg) MCHC (gm/di) Hgb Barts (% ) Other Abnormal Hgb (% ) 
1 F, A, S, Barts 93 
2 F, A, C, Barts 93 
3 F, A, Barts 87 
4 F, A, Batts 94 
5 F, A, Barts 93 
6 A, F, Barts* 90 
7 F,A 91 
8 F,A 93 
9 F, A 91 
MCV = mean corpuscular volume 
MCH = mean corpuscular hemoglobin 
28.5 
28.2 
27.7 
29.1 
29 . 5 
28 .0 
29.0 
29.2 
29 . 3 
MCHC = mean corpuscular hemoglobin concentration 
RBC = red blood cell count 
Hgb = hemoglobin 
Hct = hematocrit 
* Electrophoretic pattern at one month of age 
31.0 4.6 4.8 
30. 7 4.4 10. 6 
32.0 5 . 1 
31.4 6. 6 
32.1 4.8 
31. 6 3.0 
31.2 
31.4 
32.2 
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of a larger medical evaluation conducted under 
the aegis of the Department of Pediatrics at the 
Medical College of Virginia. As part of the study, 
capillary blood samples were drawn by a registered 
medical technologist at the various schools. Samples 
were takep. for Coulter model "S" determinations 
and hemoglobin electrophoresis. As in the earlier 
study, unopettes for the model "S" (order no. 5840, 
Becton Dickinson, Rutherford, N. J.) were used. 
These were drawn in duplicate, the model "S" 
parameters determined on both samples. Capillary 
sampks also were used for the hemoglobin elec-
trophoresis. Indices available for comparison were 
dated prior to the advent of electronic counters 
performing multiple simultaneous tests. Our ex-
perience with initial standardization of our model 
"S" showed that our norm for the automated pro-
cedures of 92 ± 6 was higher than that generally 
used· of 88 .± 8. It seemed likely, therefore, tqat 
these older data could represent values lower tqan 
might be obtained by the currently used automated 
methods. Additionally, other than the standards 
cited by Shumway (6), I am aware of no others. 
As a result, it seemed preferable to determine our own 
mean model "S" parameters for this age group. 
As noted, the recently published works did 
not specify the ages of the patients studied. It was 
assumed, therefore, that these were adults. In both 
studies, the lower limit of normal was 80. With 
Shumway's data ( 6) suggesting a lower mean MCV 
for pediatric age groups when compared with adults, 
we felt that perhaps it would be wise to include 
lower values. Thus for those studies, an MCV of 76 
or greater was used for establishment of the mean 
and those 75 or lower were excluded. It is gratifying 
to note that 26% of the children studied had MCVs 
76-79 and would have been excluded if the criteria 
of other screening studies had been used. 
For the moment, I would like to refer to the 
results not as normal but rather as "mean model 
'S' parameters." The health of the children was 
not evaluated and the sampling was random. Data 
from two children were excluded because of hemo-
globin values less than 10 but with MCV over 80. 
As a result, determination on 451 Black 
children, ages four to eight, with MCV greater than 
76 were available for analysis. The results of these 
determinations are shown in Table 3. As noted, 
these are mean model "S" parameters for the group 
studied. These show the means with one standard 
deviation as well as the range. Also shown is the 
TABLE 3 
MEAN MODEL "S" PARAMETERS 
(451 Black Children MCV > 75) 
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Lower 
Determination Mean± SD Range Toi. Limit* 
RBC 4.51 ± 0.31 3.81-5.19 4.0 
Hgb 12.3 ± 0.86 10.4- 14.8 10.9 
Hct 36.7 ± 2.4 31.1-45.1 32.7 
MCV 81.8 ± 3.3 76.0-91.0 76.4 
MCH 27. 3 ± I. 3 24 . 3-31. 3 25 .2 
MCHC 33.7±0.8 31. 9-35. 7 32.4 
* Lower Tolerance Limit = x - ks 
x = mean 
k = 1.65 (95% tolerance level) 
s = standard deviation 
lower tolerance limit using a 95 % tolerance in-
terval (k = 1.65) . With these figures we could 
be 95 % certain that 90% of the values would be 
above the lower tolerance limit shown in the right 
hand column. 
It now becomes of great interest to compare 
these results with those alluded to earlier as having 
been determined by nonautomated methods and 
reported by Shumway ( 6). This comparison is 
shown in Table 4. The similarities are remarkable, 
especially when one considers that our population 
sample was not a selected one and was from chil-
dren with Hgb greater than 10.4 gms and MCV 
76 or greater. I think we can conclude that it might 
be reasonable to accept these as normal values for 
the age group. 
Our original intent for the determination of 
the indices was to see if it would be possible to 
screen for thalassemia trait using microcytic hypo-
chromic indices as the major criteria. The spectre 
of iron deficiency, however, loomed large in front 
of us since both thalassemia trait and iron de-
RBC 
Hgb 
Hct 
MCV 
MCH 
MCHC 
TABLE 4 
Current Data 
4 . 51 ± 0.31 
12.3 ± 0 .86 
36.7 ± 2.4 
81.8 ± 3.3 
27. 3 ± I. 3 
33.7±0.8 
Shumway (6) 
4.65 ± .5 
12 .7 ± 1 
37 .0 ± 3 
80.0 ± 4 
27.0 ± 2 
34.0 ± 1 
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ficiency are characterized by microcytic hypochromic 
indices. At the time that these data were be-
ing collated for presentation, the results of the 
hemoglobin electrophoresis were not available. 
Thus, there were 84 children with MCV 75 or 
less who needed to be differentiated if possible. 
Pearson, et al. (3), in their studies, proposed a 
scheme for thalassemia trait screening. This is shown 
in a slightly modified fashion in figure 1. Note that 
the first step in screening is to classify the subjects 
into two groups according to the MCV which is 
precisely what we did. The next step involves 
quantification of A.2 hemoglobin which, as noted, 
is not at the moment available. 
This led to a search for an alternative method 
for attempting to differentiate the MCV 75 and 
below group. Recently, such a method has been 
published by England and Fraser ( 1). They re-
ported that by the use of the statistical discriminant 
function (D.F .) they were able to differentiate be-
tween ·the disorders with a 99% success rate in 
72 cases. As a result of their study, a slightly modi-
fied formulation is available and is shown as well 
as the data for the study in Table 5. Thus, it seemed 
MCV (Model "S") 
~~ 
MCV < 79 fl MCV >79 fl 
Dx: Normal 
Hgb A,> 3.5% 3.5% 
t t 
Dx: f) Thalassemia Serum iron 
/ \ 
Normal Reduced 
+ family study 
i Dx: Iron deficiency 
Dx : a Thalassemia 
Modified from Pearson, et al (3). 
Fig. I- Suggested schema for thalassemia trait screening. 
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that it might be possible to predict, in advance of 
the receipt of the electrophoretic data, the groups 
into which our 84 subjects might fall and effectively 
separate the thalassemia trait from an iron de-
ficiency. Accordingly, the appropriate data on those 
children with MCV 75 or less were substituted 
into the formula. The results are shown along with 
the normal in Table 5. It can be seen that 11 of 
the group had negative, while 73 had positive, D.F.s. 
To show the distribution, a chart like that of Eng-
land and Fraser ( 1 ) was prepared and is shown 
in figure 2. The closed circles represent those sub-
jects with a positive D.F.' and presumable iron de-
ficiency. Those with the open circles represent the 
negative D.F.' and presumable thalassemia trait. 
Since the critical data currently are missing, I think 
it is only possible to state that we are predicting 
that these are the groups into which the subjects 
fall. The data in Table 5 show certain of the mean 
values to be sufficiently different to suggest that these 
really are two distinct groups despite a few (four) 
that were too close to O to call ( fig. 2). As soon as 
the additional data are available, we will know how 
well we are able to predict. 
If I may be allowed to speculate, I expect a 
high success rate. As evidence for this rather rash 
statement, again direct your attention to figure 2. 
Note that in the D.F.' negative area [D.F.' = 
MCV -RBC - (5 x Hgb) - 3.4] there are 
four x's. While this manuscript was in preparation, 
I noted four patients' model "S" data that were 
quite like those seen in the 11 children with nega-
tive D.F.s. I felt these were suspect on the basis 
TABLE 5 
COMPARISON OF GROUPS BY MCV AND D.F.'* 
# of 
Children 
RBC 
Hgb 
Hct 
MCV 
MCH 
MCHC 
451 
MCV > 75 
4. 51±0.31 
12.3±0.86 
36.7 ± 2.4 
81.8±3.3 
27.3 ± 1.3 
33.7±0.8 
11 73 
MCV < 76 
D.F.'- D.F.'+ 
*5.54±0.19 4.86 ± 0 .28 
12.5 ± 0 . 67 11.6 ± 0. 70 
37. 7 ± 1. 79 35.2±2.14 
*68.4 ± 3. 8 *72.9 ± 2.57 
*22.6±1.75 *24.0 ± 1.15 
33 . 3 ± 1.03 33 . 1 ± 0.93 
* D.F.' = MCV - RBC - (5 X Hgb) - 3.4 
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Figure 2 
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*Elevated above normal - not quantified 
of the experience I was accumulating. Hemoglobin 
electrophoresis was performed in these, therefore, 
and the A2 hemoglobin quantified. Summary data 
on these patients are given in Table 6. Such ability 
to predict certainly suggests that the automated 
multitest apparatus has given us remarkable ability 
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TABLE 6 
Patient RBC MCV MCH D .F. % A,Hgb 
D.H. 5.65 62 20 -3 .05 6 
W.F . 6.52 64 20 -9.92 6 
A.J. 6.17 65 21 -8.5 7 
P.F. 6.16 64 20 -6.5 (*) 
* Elevated above normal- not quantified 
to select those most likely to have beta thalassemia 
trait. I await with eagerness complete collation of 
data, predictions and electrophoresis in the 84 
children noted. 
In summary, it can be said that a sample of 
multitest screening in hematology has been pre-
sented, made possible by the use of automated 
counting apparatus. The ease, precision and ac-
curacy of the determinations favor much wider 
application. To this end studies are now cropping 
up in the literature, almost with every new journal 
that hits one's desk. Our efforts presented here show 
that studies of "at risk" populations are not only 
feasible but practical. Such examples as those given, 
certainly advance our knowledge and facilitate our 
know-how in difficult diagnostic areas. 
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